Wednesday, July 14, AstraZeneca (AZ) announced that the UK’s Competition and Markets Authority (CMA) has cleared the Alexion buyout without raising any antitrust concerns.
The go-ahead follows blessings from competition authorities in the US and EU and marks the final regulatory approval the company needs to seal the deal, which is now expected to close July 21.
The transaction, unveiled in December, gives AZ additional know-how in immunology and a presence in rare diseases.
The combination of Alexion offers an immediate boost to AZ’s top line thanks mainly to complement inhibitors Soliris and Ultomiris, which together brought in US$1.37 billion in first-quarter sales. AZ also sees broad application of Alexion’s complement platform and other immunology technologies in various therapeutic areas—including oncology—to fuel future growth.
Once the takeover completes, AZ is creating a rare disease unit bearing Alexion’s name with headquarters at the US firm’s current location in Boston. The franchise will be led by Marc Dunoyer, currently AZ’s chief financial officer, who will also take on the title of chief strategy officer. His CFO role will be filled by Alexion’s CFO, Aradhana Sarin.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh